Diagnostic challenges in current laboratory practice at Italian Hemophilia Centers: findings from a nationwide survey
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Laboratory diagnosis is essential for identifying inherited bleeding disorders and monitoring therapy. We report results of a national survey by the Italian Association of Hemophilia Centers (AICE) that assesses test and reagent availability relative to guidelines and identifies improvement areas in reference laboratories (RLs) affiliated with hemophilia centers.
Methods: Forty-three RLs participating in the ECAT External Quality Assessment completed an online questionnaire of 51 items across 11 sections.
Results: Of surveyed RLs, 46.5% are located within hemophilia centers, and 53.5% are external, most within the same hospital. Most employ dedicated hemostasis personnel and use analytical platforms from Werfen, Siemens, or Stago. Nearly all perform one-stage assays for FVIII and FIX activity; 86% also use chromogenic substrate assays (CSA). Availability of CSA for FIX and capacity for CSA-based inhibitor titration are limited. Significant heterogeneity exists in reagent selection and application, notably for activated partial thromboplastin time and FVIII/FIX assays, and in von Willebrand disease (VWD) diagnostic workflows. Turnaround times are generally longer, and reagent use is more variable in external RLs.
Conclusions: Practices across several RLs do not fully align with national and international recommendations for the diagnosis and monitoring of hemophilia and VWD. Regional procurement policies influence test availability. Findings support AICE’s initiative to establish a working group to improve laboratory diagnostic standards and highlight the need for targeted training and collaboration among clinical, laboratory, and healthcare management stakeholders. These data provide a baseline for harmonizing practices, guiding procurement decisions, and prioritizing education, research, and quality improvement initiatives nationally.
Downloads
Citations
CRediT authorship contribution
Tiziano Martini, writing – original drafting; Angelo Claudio Molinari, Marina Marchetti, Alessandra Valpreda, writing – review and editing, tables preparation; all other authors, writing – manuscript review for important intellectual content. All authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Rita Carlotta Santoro, Roberto Minici, Marzia Leotta, Mariapia Falbo, Lucia Concetta Elia, Francesca Leo, Antonella Ierardi, Alessandra Strangio, Simona Prejanò, Vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1 nCoV-19 vaccine: report of two cases , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Stefano Lancellotti, Monica Sacco, Maira Tardugno, Antonietta Ferretti, Raimondo De Cristofaro, The von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno, The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Armando Tripodi, Remembering the XXVI SISET Congress and the 50th anniversary of its foundation, 2020 , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- Armando Tripodi, The introduction of the international normalized ratio as a breakthrough event in the history of thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- Luca Barcella, Chiara Ambaglio, Paolo Gritti, Francesca Schieppati, Varusca Brusegan, Eleonora Sanga, Marina Marchetti, Luca Lorini, Anna Falanga, Long-term persistence of high anti-PF4 antibodies titer in a challenging case of AZD1222 vaccine-induced thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Niccolò Bitto, Vincenzo La Mura, Anna Ludovica Fracanzani, Armando Tripodi, Is non-alcoholic fatty liver disease a prothrombotic risk factor? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro, The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Armando Tripodi, Direct oral anticoagulants: does one dose fit all? Why, when and how testing , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. 1 (2026)
- Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro, Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. 1 (2026)
